2372 related articles for article (PubMed ID: 25875246)
41. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
[TBL] [Abstract][Full Text] [Related]
42. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
43. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
Kipriyanov SM; Cochlovius B; Schäfer HJ; Moldenhauer G; Bähre A; Le Gall F; Knackmuss S; Little M
J Immunol; 2002 Jul; 169(1):137-44. PubMed ID: 12077238
[TBL] [Abstract][Full Text] [Related]
44. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Dreier T; Lorenczewski G; Brandl C; Hoffmann P; Syring U; Hanakam F; Kufer P; Riethmuller G; Bargou R; Baeuerle PA
Int J Cancer; 2002 Aug; 100(6):690-7. PubMed ID: 12209608
[TBL] [Abstract][Full Text] [Related]
45. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
46. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
47. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S
Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981
[TBL] [Abstract][Full Text] [Related]
48. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
49. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
[TBL] [Abstract][Full Text] [Related]
50. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
51. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.
Mendler CT; Friedrich L; Laitinen I; Schlapschy M; Schwaiger M; Wester HJ; Skerra A
MAbs; 2015; 7(1):96-109. PubMed ID: 25484039
[TBL] [Abstract][Full Text] [Related]
52. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
53. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Mentz K; Singer H; Stockmeyer B; Hillen W; Mackensen A; Fey GH
MAbs; 2011; 3(1):21-30. PubMed ID: 21081841
[TBL] [Abstract][Full Text] [Related]
54. [Study of specific targeting cytotoxicity mediated by anti-CD(3)/anti-CD(20) Diabody].
Xiong D; Shao X; Yang C; Xu Y; Liu H; Han J; Peng H; Yang M; Zhu Z
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):359-62. PubMed ID: 11877098
[TBL] [Abstract][Full Text] [Related]
55. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.
McAleese F; Eser M
Future Oncol; 2012 Jun; 8(6):687-95. PubMed ID: 22764766
[TBL] [Abstract][Full Text] [Related]
56. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
57. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
58. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
59. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
60. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]